Issues related to compounding and counterfeit drugs.
2025 · 4th Quarter (Oct 1 - Dec 31)
NOVO NORDISK, INC.
Filed by THE NICKLES GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- NOVO NORDISK, INC.
- Filing UUID
- 04dc516c-e1ee-4301-82e4-67c90d520e0c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.
Literal federal measure citations: H.R. 1492
Monitor issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.
Literal federal measure citations: H.R. 1, H.R. 591, H.R. 2423
Issues related to tariffs. Issues related to importation of counterfeit drugs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.